Treatment of Libman-Sacks endocarditis by combination of warfarin and immunosuppressive therapy

Sonsoz M. R., Tekin R. D., Gül A., Bugra Z., Atilgan D.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, vol.47, no.8, pp.687-690, 2019 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.5543/tkda.2019.29213
  • Journal Name: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.687-690
  • Keywords: Antiphospholipid syndrome, immunosuppressive therapy, Libman-Sacks endocarditis, systemic lupus erythematosus, warfarin, NONBACTERIAL THROMBOTIC ENDOCARDITIS, ANTIPHOSPHOLIPID SYNDROME, FOLLOW-UP, MANAGEMENT, DIAGNOSIS
  • Istanbul University Affiliated: Yes

Abstract

Antiphospholipid syndrome (APS) is a clinical disorder that creates an increased risk of arterial or venous thrombotic events or pregnancy-associated complications and includes the presence of autoantibodies against negatively charged phospholipids. This syndrome is often associated with systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). Libman-Sacks endocarditis is a form of non-bacterial thrombotic endocarditis and is infrequently seen in APS. There are few data documenting the echocardiographic response of APS valve disease to medical treatment. This is an unusual case of a young female patient with SLE and APS who had chorea and non-bacterial thrombotic aortic valve endocarditis. Echocardiography revealed that the vegetation had receded after a combination of warfarin and immunosuppressive therapy.